Drugs / PD1-TIL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03347097 | Jan 2017 → Jan 2020 | glioblastoma | Huashan Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD1-TIL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03347097 ↗ |
| Action | Activate | “which can transduce signals to activate T cells and result in tumor killing.” NCT03347097 ↗ |
| Modality | Cell therapy | “transgenic modified TIL cells” NCT03347097 ↗ |